Clinical Study Results Involving Spryng, a PetVivo Holdings, Inc. Product, Presented at the Veterinary Orthopedic Society Annual Conference in Lake Tahoe, California
MINNEAPOLIS, MN, US, Feb. 29, 2024 (GLOBE NEWSWIRE) — PetVivo Holdings, Inc. (NASDAQ:PETV & PETVW) (the “Company” or “PetVivo”) an emerging biomedical device company focused on the commercialization of innovative medical devices and therapeutics for companion animals announced that Alexander Amalfitano DVM, of Ethos Veterinary Health and Colorado Animal Specialty & Emergency (CASE) presented at the Veterinary Orthopedic Society (“VOS”) annual conference on the completion of the first cohort of dogs in a clinical study, which examined the benefit and tolerability of an intra-articular injection of collagen-elastin hydrogel microparticles (i.e. Spryng™ with OsteoCuhsion™ Technology) into the coxofemoral joint of dogs with osteoarthritis.
Related news for (PETV)
- Petvivo Holdings, Inc. to Present at the Life Sciences Virtual Investor Forum September 18, 2025
- PETVIVO HOLDINGS, INC. ANNOUNCES INVESTOR EXERCISE OF PURCHASE OPTION TIED TO SERIES B CONVERTIBLE PREFERRED STOCK OFFERING
- Digital Landia, LLC, in Cooperation with PetVivo Holdings, Inc., Announces Invite-Only MVP Availability Amid Stress-Testing & Debugging Phase
- Petvivo Holdings, Inc. and PiezoBioMembrane Inc. Announce Master Services Agreement to Jointly Develop Innovative Functional Biomaterials
- DIGITAL LANDIA, LLC IN COOPERATION WITH PETVIVO HOLDINGS, INC. UNVEILS REVOLUTIONARY AUTONOMOUS PET AI ECOSYSTEM TRANSFORMING PET CARE WITH SELF-LEARNING MULTI-AGENT AI TECHNOLOGY